Secondary Hypogonadism and Mental Health: How Low Testosterone Affects Depression, Anxiety, and Cognition

What Is Secondary Hypogonadism and Why Does It Affect the Brain?

Secondary hypogonadism originates in the hypothalamus or pituitary gland rather than the testes. The brain fails to produce adequate gonadotropin-releasing hormone (GnRH) or luteinizing hormone (LH), so the testes never receive the signal to manufacture testosterone. This distinguishes it from primary hypogonadism, where the testes themselves are damaged.

The distinction matters for mental health because the same hypothalamic-pituitary axis that controls testosterone also regulates cortisol, thyroid hormone, and growth hormone. When the central signal is disrupted, multiple hormonal cascades can falter simultaneously. A man with a pituitary adenoma, for example, may present with fatigue, depressed mood, and low libido that his primary care physician attributes to major depressive disorder, delaying the correct diagnosis by months or years.

The Endocrine Society's 2018 Clinical Practice Guideline defines male hypogonadism as total testosterone <300 ng/dL measured on at least two morning samples, combined with consistent symptoms [1]. When LH is low or inappropriately normal (<8 mIU/mL), the cause is classified as secondary. This laboratory pattern should prompt MRI of the sella turcica if testosterone is <150 ng/dL, if prolactin is elevated, or if visual field deficits are present. Missing an underlying mass lesion is one of the highest-stakes diagnostic errors in endocrinology.

Testosterone crosses the blood-brain barrier and binds androgen receptors concentrated in the hippocampus, amygdala, and prefrontal cortex. These regions govern mood regulation, threat appraisal, and executive function. That anatomy explains why low testosterone does not simply reduce sex drive; it reshapes emotional processing at a structural level [2].

The Bidirectional Link Between Low Testosterone and Depression

Depression is not just a symptom of hypogonadism. It is also a cause. The relationship runs in both directions, and understanding that cycle is necessary for effective treatment.

Chronic psychological stress and major depressive disorder raise cortisol through sustained hypothalamic-pituitary-adrenal (HPA) axis activation. Elevated cortisol directly suppresses GnRH pulsatility, which lowers LH secretion and, consequently, testosterone production [3]. A 2019 meta-analysis published in Psychoneuroendocrinology confirmed that men with major depressive disorder had significantly lower total and free testosterone compared to non-depressed controls, with a pooled effect size (Cohen's d) of 0.40 [4]. That is a moderate effect, comparable to the testosterone difference between men who sleep six hours versus eight hours per night.

On the other side, low testosterone independently predicts new-onset depressive episodes. The European Male Ageing Study (EMAS), a prospective cohort of 3,369 men aged 40 to 79, found that men with total testosterone in the lowest quintile had a 2.1-fold increased risk of developing depressive symptoms over 4.3 years of follow-up [5]. The relationship held after adjustment for BMI, alcohol use, comorbid illness, and baseline mood.

Dr. Shalender Bhasin, lead author of the Endocrine Society guideline and professor at Harvard Medical School, has stated: "Clinicians should consider measuring testosterone in men with otherwise unexplained depressive symptoms, particularly when standard antidepressant therapy has been insufficient" [1]. This recommendation stops short of universal screening but positions testosterone measurement as a second-line diagnostic step in treatment-resistant depression.

A practical clinical sequence: if a man under 50 presents with fatigue, anhedonia, low libido, and a PHQ-9 score above 10 that has not responded to first-line SSRI therapy after 8 weeks, checking a morning total testosterone, LH, FSH, and prolactin level is reasonable. A result showing total testosterone of 220 ng/dL with an LH of 4 mIU/mL points to a central problem that no amount of sertraline will fix.

What the Testosterone Trials Revealed About Mood

The Testosterone Trials (TTrials) remain the largest coordinated set of randomized controlled studies examining testosterone gel in older men with low testosterone. The Sexual Function Trial enrolled 790 men aged 65 and older with total testosterone <275 ng/dL and symptoms in at least one of three domains: sexual function, physical function, or vitality [6].

The Vitality Trial, a component of TTrials, assessed mood using the PHQ-9 depression scale. Men randomized to testosterone gel (targeting a mid-normal testosterone level) showed a statistically significant but modest improvement in PHQ-9 scores over 12 months compared to placebo. The effect was most pronounced in men who had both low testosterone and elevated baseline depressive symptoms [6]. The clinical translation: testosterone is not an antidepressant for everyone, but in men who are genuinely hypogonadal and genuinely depressed, it moves the needle.

A separate analysis from TTrials examined cognitive function. The Cognitive Function Trial found that testosterone treatment did not improve memory or executive function in the overall cohort [7]. This null result is important. It tempers the marketing claims around testosterone and "brain fog." Where testosterone does appear to help cognition is in younger men with more severe hypogonadism (total testosterone <200 ng/dL), a population not well represented in TTrials.

A 2020 systematic review and meta-analysis in JAMA Psychiatry, pooling 27 RCTs and 1,890 men, found that testosterone treatment produced a moderate antidepressant effect (effect size g = 0.21 to 95% CI 0.10 to 0.32), with stronger effects in men receiving adequate doses that achieved physiologic testosterone levels [8]. Dr. Andreas Walther, senior author, noted: "The antidepressant effect of testosterone was most strong in trials using doses sufficient to reach eugonadal levels, suggesting that underdosing explains many prior null findings" [8].

Anxiety, Irritability, and the Overlooked Emotional Spectrum

Depression dominates the research literature on hypogonadism and mental health, but anxiety may be equally common and is studied far less. Testosterone modulates GABAergic neurotransmission in the amygdala, and its metabolite allopregnanolone is a potent GABA-A receptor positive allosteric modulator. Low testosterone can reduce GABAergic tone, raising baseline anxiety and exaggerating the startle response [9].

The EMAS data showed that men in the lowest testosterone tertile reported significantly higher scores on the Beck Anxiety Inventory compared to the highest tertile (mean difference 3.2 points, p <0.01) [5]. Three points on the BAI is the difference between "minimal" and "mild" anxiety in clinical interpretation.

Irritability presents a diagnostic trap. A man whose testosterone has dropped from 550 to 180 ng/dL over two years may not describe himself as "sad." He may describe himself as angry, short-tempered, and frustrated. In clinical interviews, this irritable presentation is easily misclassified as a personality issue or attributed to life stressors. Screening with both the PHQ-9 and a targeted question about new-onset irritability increases diagnostic yield.

Sleep disruption compounds the problem. Secondary hypogonadism caused by obstructive sleep apnea (OSA) is one of the most common and most reversible forms. OSA fragments sleep architecture, suppresses slow-wave sleep (when the largest testosterone pulses occur), and raises nocturnal cortisol. A 2015 study in the Journal of Clinical Endocrinology & Metabolism demonstrated that treating severe OSA with CPAP for three months raised total testosterone by an average of 95 ng/dL without any hormonal intervention [10]. For these men, the prescription is not testosterone. It is a CPAP machine.

Opioid-Induced Hypogonadism: A Growing Cause With Psychiatric Consequences

Chronic opioid therapy has become one of the most common causes of secondary hypogonadism in men under 60. Opioids suppress hypothalamic GnRH release in a dose-dependent fashion. A 2013 cross-sectional study in the Journal of Clinical Endocrinology & Metabolism reported that 74% of men on long-term opioid therapy met biochemical criteria for hypogonadism (total testosterone <300 ng/dL), compared to 34% of age-matched controls [11].

The psychiatric implications are severe and circular. A man prescribed opioids for chronic pain develops secondary hypogonadism. His testosterone drops. He develops depression, fatigue, and reduced motivation. Those symptoms are interpreted as consequences of chronic pain rather than a treatable endocrine deficit, so his opioid dose is increased. The problem worsens.

The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend screening for hypogonadism in all men on chronic opioid therapy exceeding three months [12]. If hypogonadism is confirmed and the patient cannot taper off opioids, treatment with testosterone or, in men desiring fertility, with human chorionic gonadotropin (hCG) is indicated.

Diagnosis: Getting It Right the First Time

Misdiagnosis delays effective treatment by an average of two to three years in secondary hypogonadism cases initially labeled as psychiatric. The diagnostic process requires discipline.

Step one is confirming low testosterone. Total testosterone must be drawn between 7:00 and 10:00 AM on two separate days, because levels vary by 30% or more across the circadian cycle. A single afternoon draw of 280 ng/dL is nearly uninterpretable [1].

Step two is classifying the hypogonadism. LH and FSH levels below 8 mIU/mL in the setting of low testosterone point to a secondary (central) cause. An inappropriately normal LH (say, 5 mIU/mL when testosterone is 150 ng/dL) also qualifies, because a functioning pituitary should respond to low testosterone with LH levels above 10 mIU/mL.

Step three is identifying the underlying etiology. A prolactin level, ferritin (to screen for hemochromatosis), fasting glucose or HbA1c, TSH, and cortisol complete the basic workup. If total testosterone is <150 ng/dL, prolactin is elevated, or symptoms include headaches or visual changes, pituitary MRI is mandatory [1].

Common reversible causes that are frequently missed include:

• Obesity: adipose tissue aromatizes testosterone to estradiol, and excess estradiol suppresses GnRH. Weight loss of 10% to 15% can raise testosterone by 100 to 150 ng/dL [13].
• Obstructive sleep apnea: CPAP alone may normalize testosterone.
• Chronic opioid use: dose reduction or rotation can partially restore axis function.
• Exogenous glucocorticoids: prednisone doses above 7.5 mg/day suppress the HPG axis.

The ADA Standards of Care recommend screening men with type 2 diabetes for hypogonadism given the high co-prevalence (up to 40% in some cohorts), and the overlap of symptoms with diabetic fatigue and depression [14].

Treatment Options That Preserve Fertility and Improve Mood

Exogenous testosterone (injections, gels, or pellets) is the most direct treatment for hypogonadism. But in secondary hypogonadism, where the testes are structurally intact and the problem lies upstream, fertility-preserving alternatives are often preferred, especially in men under 45.

Clomiphene citrate (off-label) blocks estrogen feedback at the hypothalamus, raising GnRH, LH, and FSH, which in turn stimulates testicular testosterone production. A 2014 retrospective study of 86 men with secondary hypogonadism showed that clomiphene 25 mg every other day raised mean total testosterone from 228 ng/dL to 612 ng/dL over 12 months, with concurrent improvements in PHQ-9 scores [15].

Enclomiphene, the trans-isomer of clomiphene, avoids the estrogenic side effects of the cis-isomer (zuclomiphene) and has shown similar efficacy in raising testosterone. The ENCLOMIPHENE-301 trial demonstrated that enclomiphene 12.5 mg daily raised testosterone to eugonadal levels while maintaining sperm concentrations, unlike testosterone cypionate, which suppressed sperm counts to near zero [16].

Human chorionic gonadotropin (hCG) mimics LH and stimulates Leydig cells directly. Typical dosing is 1,500 to 3 to 000 IU subcutaneously two to three times per week. It preserves intratesticular testosterone and spermatogenesis. hCG is often combined with testosterone in men on TRT who wish to maintain fertility, or used as monotherapy in mild secondary hypogonadism [12].

For men who do receive testosterone replacement, the Endocrine Society guideline recommends targeting a mid-normal range (450 to 600 ng/dL), monitoring hematocrit every 6 to 12 months (testosterone stimulates erythropoiesis, and hematocrit above 54% requires dose reduction or phlebotomy), and reassessing mood symptoms at 3 and 6 months [1].

The mental health response follows a predictable timeline. Libido improvements appear within 3 to 6 weeks. Mood and energy improvements typically require 6 to 12 weeks. Full stabilization of depressive symptoms may take 3 to 6 months. If mood has not improved by 6 months despite confirmed eugonadal testosterone levels, the depression is likely independent of the hypogonadism and requires psychiatric treatment on its own merits.

When Testosterone Is Not the Answer

Not every depressed man with borderline testosterone needs hormonal treatment. A morning total testosterone of 310 ng/dL in a 55-year-old man with well-characterized major depressive disorder, normal LH, and no other hypogonadal symptoms does not warrant TRT. The Endocrine Society explicitly recommends against testosterone therapy in men with testosterone levels above 300 ng/dL [1].

Comorbid psychiatric medication use also complicates the picture. SSRIs can lower testosterone by 10% to 15% through serotonergic suppression of GnRH, and they cause sexual side effects that mimic hypogonadism (reduced libido, erectile difficulty, anorgasmia) [17]. Switching from an SSRI to bupropion, which has minimal sexual side effects and does not suppress testosterone, is sometimes more appropriate than adding TRT.

The integrated approach: treat the hypogonadism if it is biochemically confirmed and clinically significant, treat the depression with evidence-based psychotherapy or pharmacotherapy regardless, and address modifiable contributors (obesity, sleep apnea, opioid use) in parallel. Testosterone is a hormone, not a psychiatric medication, and it works best when the underlying endocrine deficit is real and measurable.

Men with a total testosterone of 180 ng/dL, an LH of 3 mIU/mL, a BMI of 42, and a PHQ-9 of 18 need a coordinated plan: weight management, sleep study, hormonal treatment to restore testosterone while pursuing fertility-preserving options if relevant, and concurrent mental health support. The first lab recheck should occur at 8 to 12 weeks after initiating therapy, with a target total testosterone of 450 to 600 ng/dL on a trough draw.